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                                                        Abstract 28 
Background:-  Fluoroquinolone resistance is mediated by mutations in the quinolone-resistance 29 
determining region (QRDR) of the topoisomerase genes. Denaturing high performance liquid 30 
chromatography (DHPLC) was evaluated for detection of clinically important mutations in gyrB 31 
among Salmonella.     32 
Method:- S. Typhi and S. ParatyphiA  characterised for mutation in QRDR of gyrA, parC and parE 33 
were studied for mutation in gyrB by DHPLC and validated by  sequencing.  34 
Result:- The DHPLC analysis was able to resolve the test mutant from isolates with wild type gyrB 35 
and distinguished mutants from other mutant by peak profile and shift in retention time. Three 36 
sequence variants were detected at codon 464, and a novel mutation Ser→Thr was also detected. 37 
gyrB mutation was associated with non classical quinolone resistance (NALS-CIPDS) in 34 isolates 38 
of S. Typhi only and was distinct from classical quinolone resistance associated with gyrA 39 
mutations (NALR-CIPDS).   40 
 41 
Conclusion: DHPLC is effective for the  detection of mutation and can reduce the need 42 
forsequencing to detect clinically  significant gyrB mutations.. 43 
 44 
Accession number:-  (GenBank accession nos. KF993966, GenBank accession no. KF993965 and 45 
GenBank accession no. KF993964).  46 
 47 
Key words: Decreased Ciprofloxacin Susceptibility, DHPLC, gyrB Mutation, Salmonella Typhi, 48 
Salmonella Paratyphi A ,  49 
1. Introduction  50 
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Salmonella enterica serovar Typhi (S. Typhi) and Salmonella enterica serovar Paratyphi A 51 
(S. Paratyphi A) cause the major human infection, enteric fever. The current WHO guidelines state 52 
that fluoroquinolones (FQ) are the optimal antimicrobials for treatment of uncomplicated enteric 53 
fever.1 Resistance to quinolones in S. Typhi and S. Paratyphi A can be caused by amino acid 54 
substitutions in the quinolone resistance-determining region (QRDR) of the DNA gyrase subunit 55 
gyrA, a key target of ciprofloxacin (CIP).2 These isolates are typically resistant to nalidixic acid 56 
(NALR, MIC≥32µg/ml) and show decreased susceptibility to ciprofloxacin (CIPDS MIC 57 
>0.064µg/ml). Mutations in the QRDR of the other subunit of DNA gyrase (gyrB) and both subunit 58 
of DNA topoisomerases IV (parC and parE) will also result in increased resistance to quinolones,3 59 
however the role of these mutations is not well studied in S. Typhi nor S. Paratyphi A. Another 60 
cause of decreased susceptibility to ciprofloxacin involves mutation in codons 464 (Ser to Phe) and 61 
466 (Glu to Asp) of the DNA gyrase subunit gyrB. These isolates remain sensitive to the 62 
recommended screening agent, nalidixic acid,4 but infected  patients are predicted to show longer 63 
times to fever clearance with increased treatment failure following ciprofloxacin therapy.2, 5   64 
In diagnostic microbiology laboratories, especially in typhoid endemic regions, the rapid 65 
detection of Salmonella with decreased susceptibility is important but the most common method, 66 
nalidixic acid resistance screening using disc diffusion, is no longer reliable.6 To detect mutations in 67 
topoisomerase genes, the ultimate method is direct sequencing but this is labour intensive and 68 
expensive. Alternative methods to sequencing include: single-strand conformational polymorphism 69 
(SSCP), mismatch amplification mutation assay (MAMA-PCR), PCR-restriction fragment length 70 
polymorphism (RFLP), high resolution melt analysis7 and Light Cycler based PCR-hybridization 71 
mutation assay. With the exception of SSCP these methods rely upon mutation-specific oligo-72 
primers (MAMAPCR), mutation-specific oligonucleotide probes (Light Cycler), and mutation-73 
specific enzymes (PCR-RFLP) and so only known mutations can be identified. SSCP relies on 74 
differential separation of DNA by gel electrophoresis and does not distinguish all mutations. A 75 
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method equivalent to direct sequencing in scope but simpler, cheaper and with high sample 76 
throughput is needed. Denaturing High Performance Liquid Chromatography (DHPLC) was 77 
developed in 1995 and has emerged as a rapid, high throughput screening method to detect 78 
mutations and polymorphisms.   79 
 Mutation detection using DHPLC involves subjecting PCR products, of wild type and test 80 
DNA sample in 1:1 mixture, to ion-pair reverse-phase liquid chromatography. Under conditions of 81 
partial heat denaturation, heteroduplexes form in PCR samples having internal sequence variation 82 
and display reduced column retention time relative to their homoduplex counterparts. Elution 83 
profiles for such samples are distinct from those having homozygous sequence, making the 84 
identification of samples harbouring polymorphisms or mutations a straight forward procedure. 85 
DHPLC is capable of detecting single nucleotide substitutions, small insertions and deletions by 86 
online UV or fluorescence monitoring within 10 minutes in unpurified amplicons as large as 1.5 kb. 87 
The objective of this study was to evaluate the application of DHPLC, in a developing country 88 
setting, as a high throughput tool for detection of clinically important mutations in bacteria using 89 
mutations associated with fluoroquinolone resistance in Salmonella as a proof of concept. 90 
 91 
2. Material and methods:- 92 
2.1 Selection of isolates:- Two hundred and six isolates of S. Typhi (n=162) and Paratyphi A 93 
(n=44), isolated between 2006-2011 were selected to represent diversity in terms of minimum 94 
inhibitory concentration (MIC) of nalidixic acid (NAL), ciprofloxacin (CIP), year of isolation and 95 
antibiotic resistance profile. MIC for NAL and CIP were determined by E-test (AB Biodisk, Solna, 96 
Sweden). Breakpoints for susceptibility and resistance for NAL and CIP were ≤16µg/ml and 97 
≥32µg/ml and ≤0.064 and ≥1µg/ml respectively (CLSI guideline 2012). Decreased ciprofloxacin 98 
susceptibility (CIPDS) was defined as MIC > 0.064 µg/ml. These isolates had been previously 99 
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characterised for mutation in QRDR of gyrA , parC and parE genes by PCR amplification and 100 
confirmed by direct sequencing.  101 
2.2. PCR 102 
DNA was extracted from isolated bacterial colonies using the Wizard® Genomic DNA 103 
Purification Kit (Promega) according to the manufacturer’s protocol. PCR was used to amplify the 104 
QRDR region of gyrB of test and control strains using primer FP: 5’-GCG CTG TCC GAA CTG 105 
TAC C– 3’ and RP: 5’-TGA TCA GCG TCG CCA CTT C-3’ with amplicon size 169bp.  The 106 
primers used in this study were designed in-house  using Generunner software (vesion 3.05) and  107 
obtained from commercial source (Eurofins, Bengaluru, India).  Thermocycler (Gradient 108 
Eppendorf) with the following conditions:  initial denaturation at 94oC for 5 min, followed by 30 109 
cycles of 45 sec at 94oC (denaturation), 45 sec at 50oC (annealing), 45 sec at 72oC (extension), and 110 
a final extension of 10 min at 72°C. PCR products were checked by 1.5% agarose gel 111 
electrophoresis in 1X TAE buffer. For antibiotic susceptibility tests and PCR S. Typhi (Ty2) and S. 112 
Paratyphi A (ATCC9150) strains were used as controls. 113 
 114 
2.3. DHPLC analysis 115 
The DHPLC analysis was performed using WAVE Nucleic acid fragment analysis system 116 
(WAVE System 4500, Transgenomic Inc.). Briefly 5µl of hybridized amplified PCR product of test 117 
and wild type strains (Ty2 and ATCC 9150) were mixed in 1:1 ratio. The above mixture of 118 
amplimers was hybridized by heating at 95°C for 3min and then cooled gradually by ramping the 119 
temperature down to 35°C in 1°C/min steps. The hybridized DNA was loaded on the 120 
DNASepCartridge (Transgenomics) with 54% elutent A (0.1 M tri-ethyl-ammonium acetate 121 
(TEAA) and 46% elutent B (0.1 M TEAA in 25% (vol/vol) acetonitrile). The predicted average 122 
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melting temperature over the whole 169bp gyrB fragment was 63.3°C. DHPLC analysis was 123 
therefore performed at temperatures: 61.3°C, 62.3°C, 63.3°C and 64.3°C at flow rate of 0.9ml/min 124 
to optimize formation of duplex DNA in gyrB gene. The DNA fragment elution profiles were 125 
captured using Transgenomic WAVE MAKER software to determine the correct partial 126 
denaturation temperature for mutation scanning based on the sequence of the wild-type DNA from 127 
S. Typhi (Ty2) and S. Paratyphi A (ATCC9150) strains. Eluted DNA fragments were detected by 128 
the system’s ultraviolet detector. DNA sequence variant detection depends on heteroduplex 129 
formation between wild-type and mutant DNA single strands. At elevated temperatures, the less 130 
thermostable heteroduplexes start to melt at the mismatched region, and as a result the DNA elutes 131 
earlier than corresponding homoduplexes. The optimal temperature to detect mutations in gyrB 132 
gene was then confirmed empirically by comparing chromatograms (peaks) obtained with retention 133 
time for PCR products from wild-type strains. Different peak profile to wild type or same peak 134 
profile but with a shift in retention time at a specific temperature were considered to indicate the 135 
presence of a mutation. Analyses of wild type DNA of S. Typhi (Ty2) and S. Paratyphi A 136 
(ATCC9150) were performed ten consecutive times to test the reproducibility of retention time. 137 
        138 
2.4. Sequencing 139 
 All isolates of S. Typhi and S. Paratyphi A had been previously sequenced for gyrA, parC 140 
and parE (Table 1). Sequencing was also performed to validate predicted mutations in gyrB region 141 
detected by DHPLC in 34 S. Typhi strains with heteroduplexes and 20 of S. Typhi and S. Paratyphi 142 
A strains with homoduplexes. 143 
For sequencing, the 50µl of amplified PCR product was run on 2% agarose gel. The desired  144 
band of the DNA was excised. The  DNA was extracted from  the gel by Qiagen gel extraction kit  145 
(QIAgen India Pvt. Ltd, New Delhi, India) and sequencing was done commercially by Macrogen 146 
(Korea). For novel mutations sequencing was in duplicate.  Sequences obtained were then 147 
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compared with available sequences on NCBI of S. Typhi strain Ty2 (Accession no. NC_004631 ) 148 
and S. Paratyphi A strain ATCC9150 (Accession no CP000026) using Fintch TV version 1.4.0 and 149 
MEGA version 5 software. 150 
 151 
3. Results  152 
3.1. Selection of isolates  153 
206  S. Typhi and S. Paratyphi A isolates were assigned to different groups based on MICs 154 
of NAL and CIP, as shown in Table 1.  Group 1 included NALS-CIPS isolates, group 2 NALR-CIPDS 155 
(classical quinolone resistance), Group 3 high level of CIP resistance and Group 4 NALS-CIPDS 156 
(non classical quinolone resistance); 34/162 S. Typhi isolates and 0/44 S. Paratyphi A isolates.  157 
 158 
3.2. Optimal temperature for mutation detection in gyrB by DHPLC 159 
A sharp peak of DHPLC chromatograms were obtained at 62.3oC which was identified as 160 
the optimal temperature for analysis of mutation in gyrB gene for both S. Typhi and Paratyphi A. 161 
Wild type isolates of both serovars gave rise to a single peak at this temperature (homoduplexes). 162 
The retention time for DNA for both S. Typhi (Ty2) and S. Paratyphi A (ATCC9150) isolates at 163 
62.3°C was between 4.76 - 4.81 and 3.88 - 3.90 min respectively.  164 
 165 
3.3. Detection of gyrB mutations by DHPLC   166 
We analyzed the gyrB QRDR by DHPLC to assess its ability to detect point mutations. A total of 167 
206 isolates of Salmonella were screened using this method. DHPLC detected 3 DNA sequence 168 
variants at Ser464 codon: Ser464-Phe, Ser464-Tyr and Ser 464-Thr which is a novel mutation, 169 
Any changes from the single-peak profile characteristic of wild-type S.Typhi (Ty2) S. 170 
Paratyphi A (ATCC9150) resulted in formation of heteroduplexes and was indicative of at least one 171 
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mutation at gyrB within the test DNA fragment. Among S. Paratyphi A isolates irrespective of their 172 
MIC values for ciprofloxacin and nalidixic acid, only a single peak profile characteristic of wild 173 
type gyrB was observed (Figure 1). 174 
Among S.Typhi isolates, DHPLC detected four different peak profiles including the wild type as 175 
shown in Figure 2. A single-peak profile characteristic of wild-type (Figure 2, peak A) gyrB was 176 
observed among groups 1, 2 and 3. Heteroduplexes were observed only among group 4 of isolates 177 
with non-classical quinolone resistance (NALS-CIPDS) indicating the presence of mutation in gyrB. 178 
All samples containing the same single-base substitutions had identical peak profiles (shown by 179 
overlaying them using the WAVEMAKER software). Single mutations at the same point but which 180 
incorporated a different substitution were easily seen as different DHPLC peak profiles, for 181 
example Ser464-Phe (Figure 2 peak C, n=31, (GenBank accession no. KF993966), and Ser464-Tyr 182 
(Figure 2 peak D, n=2, (GenBank accession no. KF993965). A novel mutation was observed at Ser 183 
464-Thr (Figure 2 peak B n=1, (GenBank accession no. KF993964). The retention time of these 184 
four peak profiles were also distinct (Table 2). Multiple mutations were ruled out by analysis at 185 
different temperature. 186 
 187 
 188 
3.4. Correlation of NAL and CIP MIC with mutations in DNA gyrase and topoisomerase  189 
genes is shown in Table 1:-  190 
S. Typhi and S. Paratyphi A group 1 isolates with wild type gyrA, gyrB and parC were 191 
susceptible to NAL and CIP (NALS-CIPS). Group 2 isolates of both serovar were uniformly 192 
associated with mutation in gyrA (Table 1) which conferred classical quinolone resistant phenotype 193 
(NALR-CIPDS). However among three S. Typhi isolates an additional mutation in parC gene was 194 
also observed. Group 3 isolates with high level of fluoroquinolone resistance were associated with 195 
double mutation in gyrA and a single mutation in parC gene. Mutation in gyrB conferred non 196 
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classical resistance phenotype (NALS-CIPDS) among S.Typhi only. Although these isolates were 197 
nalidixic acid susceptible, they were distinct from group 1 wild type isolates with NAL and CIP 198 
MIC being 2-3 and 10 fold higher respectively.  The decreased susceptibility to CIP (MIC 0.064-199 
0.5µg/ml) among gyrB mutants was twice fold less than decreased susceptibility (MIC CIP 0.064-1) 200 
associated with gyrA and parC mutation among group 1 isolates. Ser 464 Phe was observed most 201 
common mutation in gyrB. Mutations in gyrB did not co-exist with mutation in gyrA or parC gene 202 
and were not observed in S. Paratyphi A. No mutations were observed in parE gene among both 203 
serovars. 204 
  4. Discussion:- 205 
DHPLC has been used as a medical research tool since the 1990s to detect polymorphisms 206 
in human genes.8 More recently DHPLC has also been used for the separation and identification of 207 
PCR-amplified fragments from bacterial genes9 including: 16S-23S intergenic spacer region (ISR) 208 
and gyrA gene of Bacillus anthracis;10 and single nucleotide polymorphisms (SNPs) in QRDR of 209 
gyrA gene for ciprofloxacin resistance in Salmonella.11 Methods have also been developed for 210 
molecular screening and diagnosis of tumors,12 and cystic fibrosis.13 In this study we have used the 211 
DHPLC method for the detect fluoroquinolone resistance in S. Typhi and S. Paratyphi A. Resistance 212 
to quinolones is generally associated with mutation in gyrA and parC, 2, 5, 14 and the role of 213 
mutation in DNA gyrase subunit gyrB is less well described. This is probably due to the cost 214 
involved in screening all genes from several hundred clinical isolates. In the present study DHPLC 215 
was evaluated for its ability to detect SNPs or sequence variation in QRDR of gyrB among S. Typhi 216 
and Paratyphi A and results were validated by direct sequencing of amplicons. Major advantages of 217 
DHPLC are that knowledge of the exact mutation is within the QRDR of the topoisomerases 218 
involved is not necessary; automation is possible; and standard PCR can be used, so this is an ideal 219 
method for screening large number of strains. Although sequencing remains a gold standard in 220 
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SNPs discovery, DHPLC analysis is cheaper and simpler; and novel mutations can be identified. 221 
The technique is robust enough to use only one assay for each sample. Mutations are identified by a 222 
shift in retention time or a characteristic separation of homo- or heteroduplex peaks. The auto run 223 
mode of DHPLC significantly decreases handling time without the loss of assay specificity making 224 
screening relatively quick and easy (8 minutes for total run per sample after PCR which includes 225 
sample injection, column equilibration, and cleaning). For large numbers of samples automation 226 
using 96 well plates can be programmed for repeated injection and analysis at more than one 227 
temperature; this makes it a rapid and cost effective. With sufficient  evidence to satisfy clinical 228 
accreditation this method could be used to rapidly screen for resistance and so reduce the 229 
dependences  on labour intensive culture based methods. The capital cost is high (approx 110000 230 
USD) but running costs are relatively low USD 0.7.  The wave maker utility software allows 231 
analysis by both overlay of profile (to confirm any subtle changes) and detailed peak data. This 232 
allows immediate recognition of identical peaks and those that are novel. Once a library of mutation 233 
is generated, sequencing will be necessary only when a novel mutation is observed as distinct 234 
peaks. 235 
Using DHPLC we correctly identified mutations in gyrB in 34 NALS S. Typhi isolates (MIC 236 
≤16µg/ml). The DHPLC analysis was sensitive and specific and was able to resolve the test mutant 237 
from isolates with wild type gyrB and distinguished all mutants (with specific changes) from other 238 
mutant on the basis of peak profile and shift in retention time.The sequencing data is shown in 239 
Figure 3. Sequencing confirmed the DHPLC predicted SNPs. Three sequence variants were 240 
detected at codon 464 (Table 2), being Ser464-Phe (n=31) the predominant and a novel mutation 241 
Ser-464-Thr was also detected. Negative DHPLC results were confirmed by sequencing (n=20).  It 242 
confirms the presence of the wild type (susceptible) sequence rather than the absence of mutation as 243 
detected by qPCR methods. All NALS isolates with mutations at gyrB corresponded to non-classical 244 
quinolone resistance phenotype (NALS-CIPDS). This is of clear significance in clinical practice as 245 
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different study groups have already reported that patients infected with isolates showing decreased 246 
ciprofloxacin susceptibility normally experience more frequent treatment failures and phenotypic 247 
screening with nalidixic acid would not detect gyrB mediated resistance. Further gyrB mutation was 248 
not associated with high level FQ resistance, occurred singly and did not co-exist with other 249 
mutations. Previous reports have shown that DHPLC has in addition the advantage of detecting 250 
mutations in several regions of the DNA in one test sample.11 Mutations in gyrB are rare and 251 
multiple mutations were not found.  252 
 253 
5. Conclusion:-  254 
Our data show that DHPLC can be used to detect mutations in other genes conferring 255 
quinolone resistance including genes not normally associated with resistance (gyrB) and mutations 256 
outside the QRDR region which have not been thoroughly investigated. The high initial cost of the 257 
Transgenomic Wave DHPLC may be a factor preventing a wide application of this technique in 258 
diagnostic laboratories and further development is needed to perform multiplexed assay for 259 
simultaneous detection of mutations in different genes. 260 
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Legends  327 
 328 
Graph showing overlay of elution pattern of peaks with different retention time for                   329 
S. Paratyphi A and S.Typhi with mutation in gyrB (Figure 1 and Figure 2) 330 
 331 
Figure 1.  332 
DHPLC analyses of S.Paratyphi A at 62.3°C with mutations in gyrB – comparisons with 333 
ATCC9150 wild strain by the following peak pattern is showing WT ATCC9150 and test isolates, 334 
had no mutation. 335 
 336 
Figure 2  337 
DHPLC analyses of S.Typhi strains at 62.3°C with mutation in gyrB region – comparisons withTy2 338 
Wild strain by the following elution of peak patterns:  1) Peak A:-wild type Ty2, had no mutation. 339 
2) Peak B:-  Ser 464 Thr,  3) Peak C:- Ser 464 Phe and  4) Peak D:- Ser 464 Tyr.  Mutations were 340 
confirmed by sequencing. 341 
 342 
 343 
Figure 3 344 
Sequence data of showing mutations in gyrB at codon 464  345 
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1. Reference sequence of wild type gyrB S.TyphiTy2 Accession no. NC_004631.1,  346 
2. Ty2 control strain, no mutation as Serine (S) (TCC, Peak A; green colour),  347 
3. 780 july /08 sample with mutation Serine to Tyrosine (Y) (TCC→TAC: Peak D; red colour)  348 
4. 40 may/10 sample with mutation Serine to Threonine (T) (TCC→ACC, PeakB; blue colour)  349 
5. 22 aug/11 sample with mutation Serine to Phenylalanine (F) (TCC→TTC, PeakC; yellow colour)  350 
